ZBTB33 Pre-design Chimera RNAi
- Known as:
- ZBTB33 Pre-design Chimera RNAi
- Catalog number:
- H00010009-R01
- Product Quantity:
- 10 nmol
- Category:
- -
- Supplier:
- Abno
- Gene target:
- ZBTB33 Pre-design Chimera RNAi
Related genes to: ZBTB33 Pre-design Chimera RNAi
- Gene:
- ZBTB33 NIH gene
- Name:
- zinc finger and BTB domain containing 33
- Previous symbol:
- -
- Synonyms:
- ZNF-kaiso, kaiso, WUGSC:H_DJ525N14.1, KAISO, ZNF348
- Chromosome:
- Xq24
- Locus Type:
- gene with protein product
- Date approved:
- 2004-04-15
- Date modifiied:
- 2016-10-05
Related products to: ZBTB33 Pre-design Chimera RNAi
Related articles to: ZBTB33 Pre-design Chimera RNAi
- Methylation of cytosine bases in the CpG context (mCpG) is an essential regulatory mechanism cells use to spatially and temporally orchestrate access to genomic regions and mediate transcription. In many diseases, DNA methylation patterns become inappropriately distributed leading to aberrant transcriptional outcomes. Methyl-CpG binding proteins (MBPs) are key epigenetic mediators that selectively recognize mCpG sites, translating these signals into discrete transcriptional responses. ZBTB38 is a zinc finger (ZF) MBP that uniquely harbors two sets of five ZF clusters; each capable of selectively distinguishing mCpG sites. While the cognate DNA sequence and molecular basis for selective mCpG recognition have been defined for the ZBTB38 C-terminal (C-term) ZF domain, the molecular basis for differentiating DNA targets by the N-terminal (N-term) ZF domain remained uncharacterized. Here we report the mCpG-containing consensus sequence for the ZBTB38 N-term ZFs and demonstrate that unlike the other two ZBTB MBP family members ZBTB33 (Kaiso) and ZBTB4, the three shared core ZF domain discriminates against binding to TpG-containing DNA, and that at least one additional N-term ZF is required to stabilize DNA engagement. In addition, we demonstrate that each ZBTB38 ZF domain exhibits preferential target recognition for their respective cognate methylated DNA consensus motif. These findings expand understanding for how ZBTB38 differentially mediates epigenetic-based transcriptional process in normal and disease-state cells by providing new insight into the molecular basis by which the ZBTB38 N-term ZF domain differentiates DNA targets and offering further insight into the interplay between the N- and C-term ZF domains in directing cellular activities. - Source: PubMed
Publication date: 2026/05/07
Boster JaredGangi CooperHudson Nicholas OBillings Dallin EGuerra Castañaza Jenkins Brandon LeonelDing Victoria LBuck Bethany A - Individual differences in immune responses to African swine fever virus (ASFV), whether induced by vaccination or natural infection, may be linked to genetic variation in the genes involved in antigen presentation. - Source: PubMed
Publication date: 2025/12/11
Zhang FanghongNiu SiqiFrancisco Alegria AgostinhoAnzol Beneque AlbertoYao MinLiu GuopinWang JianwuHuang Tinghua - Cisplatin remains a standard first-line therapy for epithelial ovarian cancer; however, chemoresistance leads to poor prognosis and high recurrence. Analysis of The Cancer Genome Atlas confirmed improved overall survival in cisplatin-sensitive tumors, underscoring the need for strategies to overcome resistance in clinical settings. Integrative bioinformatics of cisplatin-treated ovarian cancer datasets from the Gene Expression Omnibus (n=255) identified six molecular drivers of resistance: Kaiso (ZBTB33), pregnane X receptor (PXR), NF-κB, HER2 (ERBB2), P-glycoprotein (P-gp/ABCB1), and HIF1A. These targets were validated in ovarian tumor specimens via immunohistochemistry, confirming elevated expression in chemo-resistant disease. Additionally, the quantitative real-time PCR analysis confirms the transcriptional upregulation of the six resistance-associated genes in cisplatin-resistant SKOV3 and OVCAR-5 ovarian cancer cells, consistent with the immunohistochemistry findings. The average fold change in mRNA transcripts ranged from 2.4 for P-glycoprotein to 5 for both NF-kB and Kaiso. Although less well studied in ovarian cancer, Kaiso is known to regulate EMT and tumor invasion in other solid tumors. Functional studies using SKOV3 and OVCAR-5 cell lines demonstrated that knockdown of Kaiso via RNA interference significantly increased cisplatin-induced cell death, indicating a direct role in therapeutic resistance. Furthermore, we investigated the synergistic effects of combining stearidonic acid (SDA), a plant-based omega-3 fatty acid known to inhibit NF-κB, with cisplatin on cell death in SKOV3 and OVCAR-5 cell lines, and compared the results with those of each compound used individually. Interestingly, co-treatment with stearidonic acid (SDA) synergistically enhanced the cytotoxicity of cisplatin at a lower dose in both cell models. These findings reveal a clinically relevant resistance signature and highlight the therapeutic potential of combinatorial strategies that target both transcriptional regulators (e.g., Kaiso) and inflammatory signaling (e.g., NF-κB). Dual targeting of these pathways may resensitize tumors to cisplatin and improve outcomes for patients with advanced ovarian cancer. - Source: PubMed
Publication date: 2026/01/01
Mansour Mahmoudvan Ginkel SabrinaAlata MaazBani IbrahimElhussin Isra - This study establishes a mechanistic link between sperm-specific transcriptomic profiles and hatch success, demonstrating that a six-gene panel can serve as a statistically robust predictor of hatch success in hybrid catfish aquaculture. - Source: PubMed
Publication date: 2025/11/03
Zhang YingWood Kyle RDunkleberger Thu MMartin Kaylan ARoy Luke ADunham Rex AButts Ian A EWang Xu - Obesity represents a significant public health challenge on a global scale. Bariatric surgery is an effective intervention for individuals with severe obesity, leading to the amelioration or resolution of numerous obesity-related comorbidities with improved quality of life. Numerous studies have demonstrated that bariatric surgery is more effective than medical weight management interventions for remission of type 2 diabetes (T2D) among patients with obesity; however, there is heterogeneity of response in this regard. In the current analysis, we examined critical differentially expressed genes (DEGs) in patients with obesity and T2D who had remission versus non-remission after bariatric surgery, i.e., responders versus non-responders. We downloaded the gene expression profile GSE271700 from the Gene Expression Omnibus and preprocessed it with GEO2R. 73 differential expressed genes with │ LFC │ > 1 and p value < 0.05 have been recognized in the responder group which were examined in subsequent analyses. SRSF5, MAGOH, LTF, NUP153, CAMP, CEACAM8, and HBD are identified as hub genes using cytoHubba plugin in cytoscape. Moreover, CAMP, CEACAM8, HBD, and LTF were shared between hub genes and the best module (identified using the MCODE plugin). ZBTB33, TAF1, and BCLAF1 were recognized as the most significant transcription factors, and CSNK2A1, CDK1, and MAPK14 were found as the most significant kinases. Moreover, functional analysis showed that DEGs affect mRNA processing and mRNA surveillance pathways. Innate immune response and regulation of cellular response to heat were the best results of biological processes. These results could help to better understand the differences in diabetes remission among patients with obesity. - Source: PubMed
Publication date: 2025/09/24
Mahjoubin-Tehran MaryamTalebloo JonanneGadde Kishore MSukhorukov Vasily NJamialahmadi TannazSahebkar Amirhossein